TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- Versus CY-applied NOD Mice

Overview

Journal Exp Diabetes Res

Specialty Endocrinology

Date 2011 Dec 7

PMID 22144989

Citations 8

Authors

Ercument Dirice

Sevim Kahraman

Gulsum Ozlem Elpek

Cigdem Aydin

Mustafa Kemal Balci

Abdulkadir Omer

Salih Sanlioglu

Ahter Dilsad Sanlioglu

Affiliations

Soon will be listed here.

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is an important component of the immune system. Although it is well acknowledged that it also has an important role in Type 1 Diabetes (T1D) development, this presumed role has not yet been clearly revealed. Streptozotocin (STZ) and Cyclophosphamide (CY) are frequently used agents for establishment or acceleration of T1D disease in experimental models, including the non-obese diabetic (NOD) mice. Although such disease models are very suitable for diabetes research, different expression patterns for various T1D-related molecules may be expected, depending on the action mechanism of the applied agent. We accelerated diabetes in female NOD mice using STZ or CY and analyzed the expression profiles of TRAIL ligand and receptors throughout disease development. TRAIL ligand expression followed a completely different pattern in STZ- versus CY-accelerated disease, displaying a prominent increase in the former, while appearing at reduced levels in the latter. Decoy receptor 1 (DcR1) expression also increased significantly in the pancreatic islets in STZ-induced disease. Specific increases observed in TRAIL ligand and DcR1 expressions may be part of a defensive strategy of the beta islets against the infiltrating leukocytes, while the immune-suppressive agent CY may partly hold down this defense, contributing further to diabetes development.

Citing Articles

Elevated Serum Osteoprotegerin is Associated with Reduced Risks of Albuminuria and CKD Progression in Patients with Type 2 Diabetes.

Lou X, Yang Z, Wu K, Li W, Hu W, Nie R Diabetes Metab Syndr Obes. 2022; 15:3831-3841.

PMID: 36530588 PMC: 9756793. DOI: 10.2147/DMSO.S390483.

Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.

Dadey R, Grebinoski S, Zhang Q, Brunazzi E, Burton A, Workman C Immunohorizons. 2021; 5(1):48-58.

PMID: 33483333 PMC: 8663370. DOI: 10.4049/immunohorizons.2000098.

Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.

Erendor F, Sahin E, Sanlioglu A, Balci M, Griffith T, Sanlioglu S Gene Ther. 2020; 28(3-4):130-141.

PMID: 32733091 DOI: 10.1038/s41434-020-0183-3.

Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model.

Zhou X, Zhang S, Yu F, Zhao G, Geng S, Yu W Hum Vaccin Immunother. 2019; 16(2):240-250.

PMID: 31070990 PMC: 7062422. DOI: 10.1080/21645515.2019.1616504.

The double trouble of metabolic diseases: the diabetes-cancer link.

Tudzarova S, Osman M Mol Biol Cell. 2015; 26(18):3129-39.

PMID: 26371080 PMC: 4569306. DOI: 10.1091/mbc.E14-11-1550.

References

Choi S, Noh H, Yoon J, Kang Y . Streptozotocin upregulates GAD67 expression in MIN6N8a mouse beta cells. J Autoimmun. 2002; 19(1-2):1-8. DOI: 10.1006/jaut.2002.0602. View

Kroncke K, Fehsel K, Sommer A, Rodriguez M, Kolb-Bachofen V . Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem Hoppe Seyler. 1995; 376(3):179-85. DOI: 10.1515/bchm3.1995.376.3.179. View

Mathews C . Utility of murine models for the study of spontaneous autoimmune type 1 diabetes. Pediatr Diabetes. 2005; 6(3):165-77. DOI: 10.1111/j.1399-543X.2005.00123.x. View

Yamada K, Yuan X, Ichikawa F, INADA C, Nonaka K . Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia. 1996; 39(11):1306-12. DOI: 10.1007/s001250050574. View

Thomas H, Kay T . Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes Metab Res Rev. 2000; 16(4):251-61. DOI: 10.1002/1520-7560(200007/08)16:4<251::aid-dmrr126>3.0.co;2-c. View

Hanley S, Liu S, Lipsett M, Castellarin M, Rosenberg L, Tchervenkov J . Tumor necrosis factor-alpha production by human islets leads to postisolation cell death. Transplantation. 2006; 82(6):813-8. DOI: 10.1097/01.tp.0000234787.05789.23. View

Lenzen S . The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2007; 51(2):216-26. DOI: 10.1007/s00125-007-0886-7. View

Yamamoto H, Uchigata Y, Okamoto H . Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature. 1981; 294(5838):284-6. DOI: 10.1038/294284a0. View

Atkinson M, Maclaren N . The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994; 331(21):1428-36. DOI: 10.1056/NEJM199411243312107. View

10.

Wu G, Burns T, McDonald 3rd E, Jiang W, Meng R, Krantz I . KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997; 17(2):141-3. DOI: 10.1038/ng1097-141. View

11.

Wu G, Burns T, Zhan Y, Alnemri E, El-Deiry W . Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999; 59(12):2770-5. View

12.

Reddy S, Chang M, Robinson E . Young NOD mice show increased diabetes sensitivity to low doses of streptozotocin. Ann N Y Acad Sci. 2006; 1079:109-13. DOI: 10.1196/annals.1375.015. View

13.

Koulmanda M, Qipo A, Auchincloss Jr H, Smith R . Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol. 2003; 134(2):210-6. PMC: 1808849. DOI: 10.1046/j.1365-2249.2003.02293.x. View

14.

Sanlioglu A, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I . High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas. 2008; 38(2):154-60. DOI: 10.1097/MPA.0b013e31818db9e3. View

15.

Walczak H, Degli-Esposti M, Johnson R, Smolak P, Waugh J, Boiani N . TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997; 16(17):5386-97. PMC: 1170170. DOI: 10.1093/emboj/16.17.5386. View

16.

Dirice E, Sanlioglu A, Kahraman S, Ozturk S, Balci M, Omer A . Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther. 2009; 20(10):1177-89. DOI: 10.1089/hum.2009.039. View

17.

Lutsiak M, Semnani R, De Pascalis R, Kashmiri S, Schlom J, Sabzevari H . Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2004; 105(7):2862-8. DOI: 10.1182/blood-2004-06-2410. View

18.

Pan G, ORourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J . The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276(5309):111-3. DOI: 10.1126/science.276.5309.111. View

19.

Sanlioglu A, Dirice E, Elpek O, Korcum A, Balci M, Omer A . High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas. 2008; 36(4):385-93. DOI: 10.1097/MPA.0b013e318158a4e5. View

20.

Sreenan S, Pick A, Levisetti M, Baldwin A, Pugh W, Polonsky K . Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 1999; 48(5):989-96. DOI: 10.2337/diabetes.48.5.989. View